Dr. Rapisuwon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
110 Irving St Nw
Suite C2149
Washington, DC 20010Phone+1 202-687-8901Fax+1 202-444-8829
Summary
- Dr. Suthee Rapisuwon is an oncologist in Washington, DC and is affiliated with multiple hospitals in the area, including MedStar Georgetown University Hospital and MedStar Washington Hospital Center. He received his medical degree from Mahidol University Faculty of Medicine and has been in practice 14 years. He specializes in genitourinary oncology and melanoma and is experienced in malignant melanoma, mucosal melanoma, clinical genetics, cutaneous malignant melanoma, and uveal neoplasms.
Education & Training
MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 2012 - 2015
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine/Medical Genetics and Genomics, 2007 - 2012- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Medical Genetics and Genomics, 2007 - 2012
Mahidol University Faculty of MedicineClass of 2003
Certifications & Licensure
MD State Medical License 2022 - 2025
DC State Medical License 2012 - 2024
OH State Medical License 2007 - 2013- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- American Board of Medical Genetics and Genomics Clinical Genetics and Genomics
Clinical Trials
- A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab Start of enrollment: 2017 Jul 26
- Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma Start of enrollment: 2018 Jul 26
Publications & Presentations
PubMed
- DiGeorge Syndrome Diagnosed at Age 38: Challenges in Low-resource Settings and Implications of a Missed Diagnosis.William Kuenstner, Suthee Rapisuwon, Leila Shobab
JCEM Case Reports. 2024-07-01 - Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade.Eric J Miller, Tracy L Rose, Benjamin L Maughan, Matthew I Milowsky, Mehmet A Bilen
Cancer. 2024-05-01 - Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA).Alexander Z Wei, Lanyi N Chen, Marlana Orloff, Charlotte E Ariyan, Maryam Asgari
Pigment Cell & Melanoma Research. 2023-11-01
Lectures
- Phase II single-arm multicenter study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma.2019 ASCO Annual Meeting - 6/1/2019
- Identification of a gene expression signature predictive of clinical benefit in patients with advanced mucosal melanoma (MCM) treated with immune checkpoint blockade.2019 ASCO Annual Meeting - 6/1/2019
- Analysis of the kinetics and effects of vemurafenib (V) + cobimetinib (C) on intratumoral and host immunity in patients (pts) with BRAFV600 mutant melanoma (BRAFmM): I...2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
MIBC Tumor Subtypes May Guide Neoadjuvant Chemotherapy UseNovember 30th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
